Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention

The quest for an HIV-1 therapeutic vaccine.

The hallmark of acute HIV-1 infection is overwhelming viral replication in CD4 + T cells that results in high levels of viremia. The initial peak of viral replication begins to decline simultaneously with the appearance of HIV-1–specific T cells, implicating the strong antiviral activity of these responses during acute infection [1, 2]. Several recent studies have demonstrated that the function...

Decoding the multifaceted HIV-1 virus-host interactome

Recently in BMC Medical Genomics, Tozeren and colleagues have uncovered virus-host interactions by searching for conserved peptide motifs in HIV and human proteins. Their computational model provides a novel perspective in the interpretation of high-throughput data on the HIV-host interactome.

the quest for an hiv vaccine

The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention

The human immunodeficiency virus type 1 (HIV-1) Vpr protein is an attractive target for antiretroviral drug development. The conservation both of the structure along virus evolution and the amino acid sequence in viral isolates from patients underlines the importance of Vpr for the establishment and progression of HIV-1 disease. While its contribution to virus replication in dividing and non-di...

RAR-beta(1) overexpression in chromophobe renal cell carcinoma: a novel target for therapeutic intervention?

AIM Retinoic acid (RA) has proven to possess modest but distinct activity in metastatic renal cell carcinoma (RCC), at least in a subgroup of patients. However, the exact molecular mechanisms leading to success or failure of RA application in individual patients are still unknown. As earlier studies have indicated that in RCC the RA receptor (RAR) beta might play a central role in RA signaling,...